Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary

Incidence of low grade well-differentiated neuroendocrine tumors (NET) is on the rise. The North American Neuroendocrine Tumor Society estimates that the United States has more than 150,000 gastroenteropancreatic NET patients. About 10% of metastatic NETs can be unknown primary, and due to their rar...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Oncol
Autors principals: Chauhan, Aman, Farooqui, Zainab, Murray, Le Aundra, Weiss, Heidi L., War Myint, Zin, Raajasekar, Arun Kumar A., Evers, B. Mark, Arnold, Susanne, Anthony, Lowell
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5964580/
https://ncbi.nlm.nih.gov/pubmed/29853889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/3519247
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars